TScan Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview

Tscan Therapeutics

08/08/2025 15:56

TScan Therapeutics Inc TCRX.OQ TCRX.O is expected to  show a rise in quarterly revenue when it reports  results on August 11 (estimated) for the period ending June 30 2025

The Waltham Massachusetts-based  company is expected to report a 162.1% increase in revenue to $1.405 million from $536 thousand a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

​LSEG's mean analyst estimate for TScan Therapeutics Inc is for a loss of 28 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for TScan Therapeutics Inc is $9.50, about 82.6% above its last closing price of $1.65

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.29
-0.29
-0.26
Beat
9.1
Dec. 31 2025
-0.27
-0.27
-0.30
Missed
-9.6
Sep. 30 2024
-0.29
-0.29
-0.25
Beat
13.1​
Jun. 30 2024
-0.28
-0.28
-0.28
Met
1
​​Mar. 31 2024
-0.26
-0.26
-0.32
Missed
-24.8
Dec. 31 2023
-0.26
-0.29
-0.21
Beat
27.6​
Sep. 30 2023
-0.50
-0.45
-0.24
Beat
46.9
Jun. 30 2023
-0.79
-0.78
-0.51
Beat
34.4

This summary was machine generated August 8 at 14:56 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)